NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Lithium Therapy in Kleine-Levin Syndrome
Neurol 85:1655-1662, Leu-Semenescu, S.,et al, 2015
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006
Alcohol Consumption and Risk of Stroke
JAMA 289:579-588, Reynolds,K.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Alcohol Consumption and Risk of Dementia: the Rotterdam Study
Lancet 359:281-286, Ruitenberg,A.,et al, 2002
Alcohol Consumption and Risk of Ischemic Stroke
Stroke 33:907-912,890, Djousse,L,et al, 2002
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
A 60-Year-Old Man with Parkinson's Disease
JAMA 275:716-722, Olanow,C.W., 1996
Dietary Flavonoids, Antioxidant Vitamins, and Incidence of Stroke
Arch Int Med 154:637-642, Keli,S.O.,et al, 1996
The Free Radical Hypothesis in Idiopathic Parkinsonism:Evidence Against It
Ann Neurol 32:799-803, Calne,D.B., 1992
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Therapeutic Hypothermia for Global and Focal Ischemic Brain Injury-A Cool Way to Improve Neurologic Outcomes
Neurologist 13:331-342, Hoesch,R.E. &Geocadin,R., 2007
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Aptiganel Hydrochloride in Acute Ischemic Stroke
JAMA 286:2673-2682,2718, Albers,G.W.,et al, 2001
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998
A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer's Disease
Neurol 48:1517-1521, Kawas,C.,et al, 1997
Lubeluzole Treatment of Acute Ischemic Stroke
Stroke 28:2338-2346, Grotta,J., 1997
Lubeluzole in Acute Ischemic Stroke:A Double-Blind Placebo-Controlled Phase II Trial
Stroke 27:76-81, Diener,H.C.,et al, 1996
The Relation Between Fish Consump & Stroke Incidence, NHANES I Epidemiol Study
Arch Int Med 156:537-542, Gillum,R.F.,et al, 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
Dose-Ranging Study of Riluzole in Amyotrophic Lateral Sclerosis
Lancet 347:1425-1431, Lacomblez,L.,et al, 1996
Selegiline and Mortality in Parkinson's Disease
Ann Neurol 40:841-845, Olanow,C.W.,et al, 1996
Head Injury
JNNP 58:526-539, Teasdale,G.M., 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Guidelines for the Management of Patients with Acute Ischemic Stroke
Stroke 25:1901-1914, Adams,H.P.,et al, 1994
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Head Injury
JNNP 56:440-447, Miller,J.D., 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Early Treatment of Ischemic Stroke with a Calcium Antagonist
Stroke 22:437-441, Rosenbaum,D.,et al, 1991